Global Therapeutic Vaccines Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Therapeutic Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Therapeutic Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Therapeutic Vaccines market include Agenus, AVAX Technologies, CIMAB S.A, Corixa, Dendreon, Northeast Biotherapeutics and Vaccinogen Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Therapeutic Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Therapeutic Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Therapeutic Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Therapeutic Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Vaccines sales, projected growth trends, production technology, application and end-user industry.
Therapeutic Vaccines Segment by Company
Agenus
AVAX Technologies
CIMAB S.A
Corixa
Dendreon
Northeast Biotherapeutics
Vaccinogen Inc
Therapeutic Vaccines Segment by Type
Nucleic Acid Therapeutic Vaccine
Peptide Therapeutic Vaccine
Cell Therapeutic Vaccine
Therapeutic Vaccines Segment by Application
Oncotherapy
Hepatitis B
Tuberculosis
Herpes Simplex Virus
Others
Therapeutic Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Therapeutic Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Therapeutic Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Vaccines industry.
Chapter 3: Detailed analysis of Therapeutic Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Therapeutic Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Therapeutic Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Therapeutic Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Therapeutic Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Therapeutic Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Therapeutic Vaccines market include Agenus, AVAX Technologies, CIMAB S.A, Corixa, Dendreon, Northeast Biotherapeutics and Vaccinogen Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Therapeutic Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Therapeutic Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Therapeutic Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Therapeutic Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Vaccines sales, projected growth trends, production technology, application and end-user industry.
Therapeutic Vaccines Segment by Company
Agenus
AVAX Technologies
CIMAB S.A
Corixa
Dendreon
Northeast Biotherapeutics
Vaccinogen Inc
Therapeutic Vaccines Segment by Type
Nucleic Acid Therapeutic Vaccine
Peptide Therapeutic Vaccine
Cell Therapeutic Vaccine
Therapeutic Vaccines Segment by Application
Oncotherapy
Hepatitis B
Tuberculosis
Herpes Simplex Virus
Others
Therapeutic Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Therapeutic Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Therapeutic Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Vaccines industry.
Chapter 3: Detailed analysis of Therapeutic Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Therapeutic Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Therapeutic Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Therapeutic Vaccines Sales Value (2020-2031)
- 1.2.2 Global Therapeutic Vaccines Sales Volume (2020-2031)
- 1.2.3 Global Therapeutic Vaccines Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Therapeutic Vaccines Market Dynamics
- 2.1 Therapeutic Vaccines Industry Trends
- 2.2 Therapeutic Vaccines Industry Drivers
- 2.3 Therapeutic Vaccines Industry Opportunities and Challenges
- 2.4 Therapeutic Vaccines Industry Restraints
- 3 Therapeutic Vaccines Market by Company
- 3.1 Global Therapeutic Vaccines Company Revenue Ranking in 2024
- 3.2 Global Therapeutic Vaccines Revenue by Company (2020-2025)
- 3.3 Global Therapeutic Vaccines Sales Volume by Company (2020-2025)
- 3.4 Global Therapeutic Vaccines Average Price by Company (2020-2025)
- 3.5 Global Therapeutic Vaccines Company Ranking (2023-2025)
- 3.6 Global Therapeutic Vaccines Company Manufacturing Base and Headquarters
- 3.7 Global Therapeutic Vaccines Company Product Type and Application
- 3.8 Global Therapeutic Vaccines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Therapeutic Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Therapeutic Vaccines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Therapeutic Vaccines Market by Type
- 4.1 Therapeutic Vaccines Type Introduction
- 4.1.1 Nucleic Acid Therapeutic Vaccine
- 4.1.2 Peptide Therapeutic Vaccine
- 4.1.3 Cell Therapeutic Vaccine
- 4.2 Global Therapeutic Vaccines Sales Volume by Type
- 4.2.1 Global Therapeutic Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Therapeutic Vaccines Sales Volume by Type (2020-2031)
- 4.2.3 Global Therapeutic Vaccines Sales Volume Share by Type (2020-2031)
- 4.3 Global Therapeutic Vaccines Sales Value by Type
- 4.3.1 Global Therapeutic Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Therapeutic Vaccines Sales Value by Type (2020-2031)
- 4.3.3 Global Therapeutic Vaccines Sales Value Share by Type (2020-2031)
- 5 Therapeutic Vaccines Market by Application
- 5.1 Therapeutic Vaccines Application Introduction
- 5.1.1 Oncotherapy
- 5.1.2 Hepatitis B
- 5.1.3 Tuberculosis
- 5.1.4 Herpes Simplex Virus
- 5.1.5 Others
- 5.2 Global Therapeutic Vaccines Sales Volume by Application
- 5.2.1 Global Therapeutic Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Therapeutic Vaccines Sales Volume by Application (2020-2031)
- 5.2.3 Global Therapeutic Vaccines Sales Volume Share by Application (2020-2031)
- 5.3 Global Therapeutic Vaccines Sales Value by Application
- 5.3.1 Global Therapeutic Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Therapeutic Vaccines Sales Value by Application (2020-2031)
- 5.3.3 Global Therapeutic Vaccines Sales Value Share by Application (2020-2031)
- 6 Therapeutic Vaccines Regional Sales and Value Analysis
- 6.1 Global Therapeutic Vaccines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Therapeutic Vaccines Sales by Region (2020-2031)
- 6.2.1 Global Therapeutic Vaccines Sales by Region: 2020-2025
- 6.2.2 Global Therapeutic Vaccines Sales by Region (2026-2031)
- 6.3 Global Therapeutic Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Therapeutic Vaccines Sales Value by Region (2020-2031)
- 6.4.1 Global Therapeutic Vaccines Sales Value by Region: 2020-2025
- 6.4.2 Global Therapeutic Vaccines Sales Value by Region (2026-2031)
- 6.5 Global Therapeutic Vaccines Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Therapeutic Vaccines Sales Value (2020-2031)
- 6.6.2 North America Therapeutic Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Therapeutic Vaccines Sales Value (2020-2031)
- 6.7.2 Europe Therapeutic Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Therapeutic Vaccines Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Therapeutic Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Therapeutic Vaccines Sales Value (2020-2031)
- 6.9.2 South America Therapeutic Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Therapeutic Vaccines Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Therapeutic Vaccines Sales Value Share by Country, 2024 VS 2031
- 7 Therapeutic Vaccines Country-level Sales and Value Analysis
- 7.1 Global Therapeutic Vaccines Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Therapeutic Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Therapeutic Vaccines Sales by Country (2020-2031)
- 7.3.1 Global Therapeutic Vaccines Sales by Country (2020-2025)
- 7.3.2 Global Therapeutic Vaccines Sales by Country (2026-2031)
- 7.4 Global Therapeutic Vaccines Sales Value by Country (2020-2031)
- 7.4.1 Global Therapeutic Vaccines Sales Value by Country (2020-2025)
- 7.4.2 Global Therapeutic Vaccines Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.9.2 France Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.16.2 China Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.19.2 India Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Therapeutic Vaccines Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Therapeutic Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Therapeutic Vaccines Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Agenus
- 8.1.1 Agenus Comapny Information
- 8.1.2 Agenus Business Overview
- 8.1.3 Agenus Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Agenus Therapeutic Vaccines Product Portfolio
- 8.1.5 Agenus Recent Developments
- 8.2 AVAX Technologies
- 8.2.1 AVAX Technologies Comapny Information
- 8.2.2 AVAX Technologies Business Overview
- 8.2.3 AVAX Technologies Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.2.4 AVAX Technologies Therapeutic Vaccines Product Portfolio
- 8.2.5 AVAX Technologies Recent Developments
- 8.3 CIMAB S.A
- 8.3.1 CIMAB S.A Comapny Information
- 8.3.2 CIMAB S.A Business Overview
- 8.3.3 CIMAB S.A Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.3.4 CIMAB S.A Therapeutic Vaccines Product Portfolio
- 8.3.5 CIMAB S.A Recent Developments
- 8.4 Corixa
- 8.4.1 Corixa Comapny Information
- 8.4.2 Corixa Business Overview
- 8.4.3 Corixa Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Corixa Therapeutic Vaccines Product Portfolio
- 8.4.5 Corixa Recent Developments
- 8.5 Dendreon
- 8.5.1 Dendreon Comapny Information
- 8.5.2 Dendreon Business Overview
- 8.5.3 Dendreon Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Dendreon Therapeutic Vaccines Product Portfolio
- 8.5.5 Dendreon Recent Developments
- 8.6 Northeast Biotherapeutics
- 8.6.1 Northeast Biotherapeutics Comapny Information
- 8.6.2 Northeast Biotherapeutics Business Overview
- 8.6.3 Northeast Biotherapeutics Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Northeast Biotherapeutics Therapeutic Vaccines Product Portfolio
- 8.6.5 Northeast Biotherapeutics Recent Developments
- 8.7 Vaccinogen Inc
- 8.7.1 Vaccinogen Inc Comapny Information
- 8.7.2 Vaccinogen Inc Business Overview
- 8.7.3 Vaccinogen Inc Therapeutic Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Vaccinogen Inc Therapeutic Vaccines Product Portfolio
- 8.7.5 Vaccinogen Inc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Therapeutic Vaccines Value Chain Analysis
- 9.1.1 Therapeutic Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Therapeutic Vaccines Sales Mode & Process
- 9.2 Therapeutic Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Therapeutic Vaccines Distributors
- 9.2.3 Therapeutic Vaccines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


